Nanologica AB (NICA) - Total Assets
Based on the latest financial reports, Nanologica AB (NICA) holds total assets worth Skr88.11 Million SEK (≈ $9.48 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nanologica AB net assets for net asset value and shareholders' equity analysis.
Nanologica AB - Total Assets Trend (2012–2025)
This chart illustrates how Nanologica AB's total assets have evolved over time, based on quarterly financial data.
Nanologica AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanologica AB's total assets of Skr88.11 Million consist of 76.8% current assets and 23.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 4.0% |
| Accounts Receivable | Skr4.69 Million | 5.3% |
| Inventory | Skr27.72 Million | 31.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr9.46 Million | 10.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Nanologica AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanologica AB (NICA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanologica AB's current assets represent 76.8% of total assets in 2025, an increase from 15.8% in 2012.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2025, down from 7.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 12.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 31.5% of total assets.
Nanologica AB Competitors by Total Assets
Key competitors of Nanologica AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Nanologica AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.65 | 4.82 |
| Quick Ratio | 1.09 | 1.17 | 4.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr30.99 Million | Skr44.76 Million | Skr72.66 Million |
Nanologica AB - Advanced Valuation Insights
This section examines the relationship between Nanologica AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -38.4% |
| Total Assets | Skr88.11 Million |
| Market Capitalization | $5.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanologica AB's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nanologica AB's assets decreased by 38.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanologica AB (2012–2025)
The table below shows the annual total assets of Nanologica AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr88.11 Million ≈ $9.48 Million |
-38.43% |
| 2024-12-31 | Skr143.10 Million ≈ $15.40 Million |
+84.81% |
| 2023-12-31 | Skr77.43 Million ≈ $8.33 Million |
-49.89% |
| 2022-12-31 | Skr154.51 Million ≈ $16.63 Million |
+57.16% |
| 2021-12-31 | Skr98.32 Million ≈ $10.58 Million |
-32.82% |
| 2020-12-31 | Skr146.34 Million ≈ $15.75 Million |
+246.08% |
| 2019-12-31 | Skr42.29 Million ≈ $4.55 Million |
+23.18% |
| 2018-12-31 | Skr34.33 Million ≈ $3.69 Million |
+32.48% |
| 2017-12-31 | Skr25.91 Million ≈ $2.79 Million |
-18.69% |
| 2016-12-31 | Skr31.87 Million ≈ $3.43 Million |
-2.74% |
| 2015-12-31 | Skr32.77 Million ≈ $3.53 Million |
+67.22% |
| 2014-12-31 | Skr19.60 Million ≈ $2.11 Million |
+40.98% |
| 2013-12-31 | Skr13.90 Million ≈ $1.50 Million |
+114.36% |
| 2012-12-31 | Skr6.48 Million ≈ $697.79K |
-- |
About Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separatio… Read more